You are here

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Last updated on May 13, 2019

FOR MORE INFORMATION
Study Location
Karmanos Cancer Institute
Detroit, Michigan, 48201 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically confirmed adenocarcinoma of the prostate without
neuroendocrine differentiation, or signet cell or small cell features;

- Presence of bone metastatic disease as assessed by at least two lesions on whole body
metastable technetium-methylene diphosphonate (99mTc-MDP) bone scintigraphy;

- Throughout the study, ongoing androgen deprivation therapy with a luteinizing
hormone-releasing hormone (LHRH) analogue or prior bilateral orchiectomy (medical or
surgical castration);

- Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening;

- Progressive disease on androgen deprivation therapy at screening defined as a minimum
of two sequentially rising prostate-specific antigen (PSA) values (PSA1 PSA3);

- The screening PSA (PSA3) must be ≥ 2 μg/L (≥ 2 ng/mL).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra
223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the
CRPC setting for the treatment of prostate cancer or participation in a clinical trial
of an investigational agent that inhibits the androgen receptor or androgen synthesis
(unless treatment was placebo);

- Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase
inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy)
within 4 weeks before enrollment;

- Initiation of new treatment with denosumab, bisphosphonates, or systemic
corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;

- Use of an investigational agent within 4 weeks before the screening visit;

- Radiation therapy to bone within 4 weeks before enrollment;

- Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;

- Screening 99mTc-MDP bone scintigraphy showing a superscan;

- Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;

- Current or previously treated brain metastasis or active leptomeningeal disease;

- History of seizure any time in the past for any reason or any condition that may
predispose to seizures.

NCT02384382
Pfizer
Active, not recruiting
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hormone Receptor Positive Advanced Breast Cancer, Metastatic Breast Cancer, Human Epidermal Receptor 2 Negative Advanced Breast Cancer, Castration Resistant Prostate Cancer
NCT03685591
All Genders
18+
Years
Multiple Sites
Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03460977
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now